MDT - Medtronic: Buy This Dividend Aristocrat Diamond In The Rough Now

2024-03-27 08:00:00 ET

Summary

• Medtronic has upped its dividend for 46 consecutive years.
• The MedTech company topped analysts' expectations in the fiscal third quarter for revenue and non-GAAP EPS.
• Medtronic's financial health is vibrant enough to possess an A rating from S&P on a stable outlook.
• Shares of the MedTech leader could be priced 24% below fair value.
• Medtronic may be poised to generate robust total returns in the long term.

My investing strategy naturally attracts me to Dividend Aristocrats on a routine basis. No company is perfect, but companies that belong to this distinguished class didn't get there (or stay there) by accident.

Upping a dividend for at least 25 consecutive years and being dominant enough to be a component of the S&P 500 ( SP500 ) is no small feat. Such an accomplishment often requires an impressive competitive position, steady profitability, and a strong balance sheet....

For further details see: